Next Article in Journal
Development of the Precision Link Biobank at Boston Children’s Hospital: Challenges and Opportunities
Next Article in Special Issue
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
Previous Article in Journal
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
Previous Article in Special Issue
Variation in CYP2A6 Activity and Personalized Medicine
Article Menu

Export Article

Open AccessFeature PaperReview
J. Pers. Med. 2017, 7(4), 20; https://doi.org/10.3390/jpm7040020

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen

1
Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5A5, Canada
2
Department of Medicine, Division of Clinical Pharmacology, Western University, London, ON N6A 5A5, Canada
3
Department of Physiology and Pharmacology, Western University, London, ON N6A 5A5, Canada
4
Department of Oncology, Western University, London, ON N6A 5A5, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen B. Liggett
Received: 25 October 2017 / Revised: 23 November 2017 / Accepted: 7 December 2017 / Published: 13 December 2017
(This article belongs to the Special Issue Cytochrome P450 Variation in Pharmacogenomics)
Full-Text   |   PDF [654 KB, uploaded 13 December 2017]   |  

Abstract

The use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we have gained over the past ten years of running a personalized medicine program, we will offer our perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and tamoxifen therapy. View Full-Text
Keywords: pharmacogenomics; warfarin; tamoxifen; cytochrome P450 pharmacogenomics; warfarin; tamoxifen; cytochrome P450
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wigle, T.J.; Jansen, L.E.; Teft, W.A.; Kim, R.B. Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. J. Pers. Med. 2017, 7, 20.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top